Wind统计显示，9月2日，科创板两融余额合计2308.39亿元，较上一交易日减少0.67亿元。其中，融资 余额合计2300.51亿元，较上一交易日减少0.68亿元；融券余额合计7.88亿元，较上一交易日增加0.01亿 元。 （文章来源：证券时报网） 从个股来看，9月2日有305只科创板个股获融资净买入，净买入金额在5000万元以上的有18股。其中， 百济神州获融资净买入额居首，净买入3.52亿元；融资净买入金额居前的还有华虹公司、绿的谐波、上 纬新材、凌云光等股，净买入金额均超1亿元。 ...

Group 1 - On September 2, among the 31 first-level industries tracked by Shenwan, 14 industries experienced net financing inflows, with the non-bank financial sector leading at a net inflow of 1.468 billion yuan [1] - Other industries with significant net financing inflows included pharmaceuticals and biotechnology, non-ferrous metals, chemicals, and oil and petrochemicals, each exceeding 100 million yuan in net inflow [1] Group 2 - A total of 1,658 individual stocks received net financing inflows on September 2, with 96 stocks having net inflows exceeding 50 million yuan [1] - Among these, 37 stocks had net financing inflows exceeding 100 million yuan, with Shenghong Technology leading at a net inflow of 1.367 billion yuan [1] - Other notable stocks with significant net inflows included Dongfang Wealth, Top Group, BeiGene, Data Port, Pacific, Sanhua Intelligent Control, Kunlun Wanwei, and Huahong Semiconductor, each with net inflows exceeding 200 million yuan [1]

Market Overview - The Hang Seng Index (HSI) closed at 25,485.70, down by 10.85 points or 0.04% as of September 2, 16:00 Eastern Time [1] - The index reached a high of 25,496.61 and a low of 25,284.62 during the trading session, with a trading volume of 95.8438 million [1] - The 52-week high for the index is 25,778.47, while the 52-week low is 17,034.99, indicating a trading range of 0.83% [1] Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 100.038, up by 0.29% compared to the Hong Kong close [2] - Tencent Holdings closed at HKD 603.227, reflecting an increase of 0.45% from the Hong Kong close [2] Individual Stock Movements - Tencent Holdings (00700) latest price is HKD 600.500, down by HKD 4.500 or 0.74% [3] - Alibaba Group (09988) latest price is HKD 134.700, down by HKD 2.400 or 1.75% [3] - China Construction Bank (00939) latest price is HKD 7.700, up by HKD 0.150 or 1.99% [3] - Xiaomi Group (01810) latest price is HKD 55.850, up by HKD 1.850 or 3.43% [3] - AIA Group (01299) latest price is HKD 72.700, down by HKD 1.400 or 1.89% [3] - Hong Kong Exchanges and Clearing (00388) latest price is HKD 443.600, down by HKD 4.400 or 0.98% [3] - JD.com (09618) latest price is HKD 119.600, down by HKD 1.800 or 1.48% [3]

Group 1: Long-term Strategic Moves - Changchun High-tech announced plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange, aiming to enhance its global strategy and international brand image despite a decline in revenue and net profit in the first half of the year [1] - The stock price of BeiGene reached a historical high of 346 CNY per share, with a market capitalization surpassing 500 billion CNY, indicating strong market competitiveness and investor preference for high-growth potential in the innovative drug sector [2] Group 2: Clinical Trials and Research Developments - Eli Lilly terminated two Phase II clinical trials for the small molecule GLP-1 receptor agonist Naperiglipron due to commercial strategy reasons, while one ongoing study is expected to conclude next year, which will influence the project's future direction [3] - Canfite BioPharma completed patient enrollment for a Phase III clinical trial of its PD-1/VEGF bispecific antibody, which could provide compelling data for treating advanced biliary tract malignancies and potentially fill a market gap if approved [4] Group 3: Corporate Restructuring - WuXi AppTec announced the transfer of 98.9% equity in Shanghai Hualian Pharmaceutical to a newly established wholly-owned subsidiary, which will not affect the operational activities or financial performance of the target company, but aims to optimize the organizational structure [5]

Summary of Key Points Core Viewpoint - The stock of BeiGene, Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 30% over three consecutive trading days from August 28 to September 1, 2025, prompting a regulatory announcement regarding the situation [1]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly, with a cumulative deviation of over 30% during the specified trading days, which is classified as abnormal trading behavior according to the Shanghai Stock Exchange regulations [1]. - The company confirmed that its production and operational activities are normal, with no significant changes in the market environment or industry policies [1]. Group 2: Company Verification - The company conducted a self-examination and found no major undisclosed events that could impact stock prices, nor any media reports or market rumors that could significantly affect the stock [1]. - There were no significant events or information that should have been disclosed according to the relevant regulations, and no insider trading activities were reported among directors or senior management during the abnormal trading period [1]. Group 3: Board of Directors Statement - The Board of Directors confirmed that, apart from disclosed matters, there are no undisclosed items that could materially affect the company's stock price or related trading instruments [1].

Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report for the first half of 2025, which showed a total revenue of 17.518 billion yuan, a year-on-year growth of 46.03% [1] Financial Performance - The total revenue for the first half of 2025 reached 17.518 billion yuan, with product revenue accounting for 17.36 billion yuan, reflecting a year-on-year increase of 45.8% [1] - The company achieved a net profit of 450 million yuan, marking its first profitable quarter of the year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa (Zebutinib capsules) and Tislelizumab (anti-PD-1 monoclonal antibody), as well as increased sales from Amgen licensed products [1] - Brukinsa demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Breakdown - Global sales of Brukinsa reached 12.527 billion yuan, representing a year-on-year growth of 56.2% [1] - In the U.S. market, sales of Brukinsa amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Brukinsa has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]

Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report for the first half of 2025, which showed a total revenue of 17.518 billion yuan, a year-on-year growth of 46.03% [1] Financial Performance - The company reported total revenue of 17.518 billion yuan for the first half of 2025, marking a 46.03% increase year-on-year [1] - Product revenue reached 17.36 billion yuan, reflecting a year-on-year growth of 45.8% [1] - The net profit for the company was 450 million yuan, marking its first return to profitability this year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa (Zebutinib) and Tazverik (Tazemetostat), as well as increased sales from Amgen licensed products [1] - Zebutinib demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Data - Global sales of Zebutinib reached 12.527 billion yuan, representing a year-on-year growth of 56.2% [1] - In the U.S. market, Zebutinib sales amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Zebutinib has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]

Core Viewpoint - BeiGene (ONC.US) experienced a significant increase of over 9%, closing at $334.20, following the release of its financial report indicating a strong revenue growth and a return to profitability in the first half of 2025 [1] Financial Performance - In the first half of 2025, the company achieved total revenue of 17.518 billion yuan, representing a year-on-year growth of 46.03% [1] - Product revenue reached 17.36 billion yuan, with a year-on-year increase of 45.8% [1] - The company reported a net profit of 450 million yuan, marking its first return to profitability this year [1] Product Performance - The growth in product revenue was driven by sales increases of self-developed products, namely Brukinsa® (Zebutinib capsules) and Tislelizumab, as well as increased sales from Amgen licensed products [1] - Zebutinib demonstrated outstanding performance, becoming the leading BTK inhibitor in both the U.S. and global markets [1] Sales Data - Global sales of Zebutinib reached 12.527 billion yuan, reflecting a year-on-year growth of 56.2% [1] - In the U.S. market, sales of Zebutinib amounted to 8.958 billion yuan, with a year-on-year increase of 51.7% [1] - Zebutinib has rapidly gained adoption among patients and physicians in the U.S. due to its best-in-class clinical characteristics, making it the largest and fastest-growing product in the market [1]

（文章来源：证券日报） 证券日报网讯 9月2日晚间，百济神州发布公告称，公司股票于2025年8月28日、2025年8月29日和2025 年9月1日连续三个交易日内日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动情形。经自 查，公司不存在应披露而未披露的重大事项，目前生产经营正常，未发生重大变化。公司股价短期波动 幅度较大，敬请投资者注意投资风险。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has exceeded performance expectations in the first half of 2025, leading to an upward revision of the full-year performance guidance [8] - The revenue for the first half of 2025 reached USD 2.43 billion, a year-on-year increase of 42%, driven by the strong sales of core product Zebutini in the US and continued growth in Europe [8] - The company is expected to maintain steady revenue growth over the next three years, with significant profit release anticipated in the coming years [8] Financial Forecasts - Total revenue projections are as follows: - 2023: CNY 17,423 million - 2024: CNY 27,214 million (YoY +56.19%) - 2025: CNY 36,720 million (YoY +34.93%) - 2026: CNY 44,798 million (YoY +22.00%) - 2027: CNY 55,998 million (YoY +25.00%) [1][9] - The net profit attributable to the parent company is forecasted to improve significantly: - 2023: CNY -6,715.86 million - 2024: CNY -4,978.29 million - 2025: CNY 812.75 million (YoY +116.33%) - 2026: CNY 4,168.46 million (YoY +412.88%) - 2027: CNY 9,542.78 million (YoY +128.93%) [1][9] - The latest diluted EPS projections are: - 2023: CNY -4.70 - 2024: CNY -3.48 - 2025: CNY 0.57 - 2026: CNY 2.91 - 2027: CNY 6.67 [1][9] Key Catalysts - Important catalysts include the upcoming data readout for Sonrotoclax (BCL2 inhibitor) in late 2025 and the initiation of head-to-head trials against rival therapies [8] - The company is also advancing its pipeline in solid tumors and inflammation/immunology, with several clinical trials expected to start in 2026 [8]